Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sensitizing Potential of FMX-101 in Healthy Volunteers
NCT04052711Phase 1Completed
- Sponsor
- Vyne Therapeutics
- Start
- Sep 2016
- Primary completion
- Nov 2016
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, single-blind trial in acne vulgaris comparing FMX-101 with Vehicle (2 arms). Primary endpoint: Assessment of recurrence of a cutaneous response at Rechallenge equivalent to or more severe than that observed at Challenge at 8 weeks. Started Sep 2016; status: completed.
02
Drugs
minocycline
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT04052711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04052711.